Promotional information from Mundipharma Pharmaceuticals ltd.

References Prescribing information and adverse events reporting

Uncontrolled blood sugar
can't wait

INVOKANA (canagliflozin) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise.1

Monotherapy - when metformin is considered inappropriate.1
Add-on therapy - with other glucose-lowering medicinal products.1

Tablets not shown to actual size.

Learn more about INVOKANA dosing ›

Why INVOKANA?

Reduce blood sugar

Only INVOKANA offloads up to 119 g of glucose per day (equivalent to 476 calories).1,3,4

View the data vs other SGLT2 inhibitors ›

Lower HbA1c levels

INVOKANA 300 mg is the only sodium glucose cotransporter2 inhibitor (SGLT2i) to have demonstrated >1% reductions in HbA1c (10.8 mmol/mol) from a baseline HbA1c of

≤ 8.1%, in four phase III clinical trials.5-8

At 26 weeks, 300 mg INVOKANA decreased:1,8
body weight by 3.7 kg from baseline (94.4 kg)
systolic blood pressure by 4.7 mmHg from baseline (126.7 mmHg)

In 6.5 years of long-term data from CANVAS program in 10,000 + patients…10

Compared to placebo, when added to standard of care INVOKANA demonstrated:

Long-term cardiovascular benefits:10

  • a 14% reduction in the risk of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke10
    • 3-point MACE*; hazard ratio (HR): 0.86; 95% confidence interval (CI):0.75-0.97; p<0.001 and p<0.02 for superiority10
  • a 33% reduction in risk of hospitalisation for heart failure10
    • HR: 0.67; 95% CI: 0.52-0.8710

*Major adverse cardiovascular events (MACE) was a composite primary outcome of death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke.

Improved renal outcomes:

  • a 47% relative risk reduction in time to first adjudicated nephropathy event (doubling of serum creatinine, need for renal replacement therapy, and renal death)9
    • HR: 0.53; 95% CI 0.33- 0.849
  • a 27% reduction in the progression of albuminuria in patients with normo- or micro-albuminuria10
    • HR: 0.73; 95% CI: 0.67-0.7910
View the ADA/EASD guideline recommendations for use of SGLT2is, including INVOKANA ›